Shepherd Financial Partners LLC Buys 350 Shares of Eli Lilly and Company (NYSE:LLY)

Shepherd Financial Partners LLC boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,507 shares of the company's stock after purchasing an additional 350 shares during the quarter. Eli Lilly and Company comprises approximately 0.9% of Shepherd Financial Partners LLC's portfolio, making the stock its 29th biggest holding. Shepherd Financial Partners LLC's holdings in Eli Lilly and Company were worth $7,852,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of LLY. Capital & Planning LLC increased its position in shares of Eli Lilly and Company by 15.6% during the 4th quarter. Capital & Planning LLC now owns 481 shares of the company's stock valued at $371,000 after purchasing an additional 65 shares during the last quarter. Garner Asset Management Corp lifted its position in Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after buying an additional 12 shares during the last quarter. Brighton Jones LLC lifted its position in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Eli Lilly and Company in the fourth quarter worth approximately $49,534,000. Finally, Revolve Wealth Partners LLC grew its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $791.61 on Wednesday. The business has a 50 day moving average of $777.90 and a 200 day moving average of $801.70. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a market cap of $750.24 billion, a PE ratio of 64.41, a P/E/G ratio of 1.18 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the previous year, the firm posted $2.58 earnings per share. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Finally, Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.